ATLANTA, July 03, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against officers of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ:BOLT). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information, regarding the Company's business, operations, and prospects, including allegations that: (i) Bolt's product, BDC-1001, was less effective than the Company had represented to investors and was in fact unlikely to meet its pre-defined success criteria; (ii) accordingly, Defendants overstated the clinical and/or commercial prospects of Bolt's product pipeline, on which the ...
BOLT) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm>Full story available on Benzinga.com